Search Results - "PRICE, David A"

Refine Results
  1. 1

    Five-Year Graft Survival of Descemet Membrane Endothelial Keratoplasty (EK) versus Descemet Stripping EK and the Effect of Donor Sex Matching by Price, David A., Kelley, Meagan, Price, Francis W., Price, Marianne O.

    Published in Ophthalmology (Rochester, Minn.) (01-10-2018)
    “…To determine whether the reduced risk of immunologic rejection with Descemet membrane endothelial keratoplasty (DMEK) results in a 5-year survival advantage…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules by Pye, Cameron R, Hewitt, William M, Schwochert, Joshua, Haddad, Terra D, Townsend, Chad E, Etienne, Lyns, Lao, Yongtong, Limberakis, Chris, Furukawa, Akihiro, Mathiowetz, Alan M, Price, David A, Liras, Spiros, Lokey, R. Scott

    Published in Journal of medicinal chemistry (09-03-2017)
    “…Macrocyclic peptides are considered large enough to inhibit “undruggable” targets, but the design of passively cell-permeable molecules in this space remains a…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Fmoc-Based Synthesis of Disulfide-Rich Cyclic Peptides by Cheneval, Olivier, Schroeder, Christina I, Durek, Thomas, Walsh, Phillip, Huang, Yen-Hua, Liras, Spiros, Price, David A, Craik, David J

    Published in Journal of organic chemistry (20-06-2014)
    “…Disulfide-rich cyclic peptides have exciting potential as leads or frameworks in drug discovery; however, their use is faced with some synthetic challenges,…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16

    Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable by Nielsen, Daniel S., Hoang, Huy N., Lohman, Rink-Jan, Hill, Timothy A., Lucke, Andrew J., Craik, David J., Edmonds, David J., Griffith, David A., Rotter, Charles J., Ruggeri, Roger B., Price, David A., Liras, Spiros, Fairlie, David P.

    Published in Angewandte Chemie International Edition (03-11-2014)
    “…The use of peptides in medicine is limited by low membrane permeability, metabolic instability, high clearance, and negligible oral bioavailability. The…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab by Ming, Qianqian, Antfolk, Daniel, Price, David A., Manturova, Anna, Medina, Elliot, Singh, Srishti, Mason, Charlotte, Tran, Timothy H., Smalley, Keiran S. M., Leung, Daisy W., Luca, Vincent C.

    Published in Nature communications (29-08-2024)
    “…The immune checkpoint protein, Lymphocyte activation gene-3 (LAG3), binds Major Histocompatibility Complex Class II (MHC-II) and suppresses T cell activation…”
    Get full text
    Journal Article
  19. 19
  20. 20